Mergers and acquisitions
The marriage of Teladoc Health and Livongo stood out amidst a quarter with relatively few M&A deals.
InfiniteMD was designed to help patients get more information about their condition via virtual visits.
The deal joins each company's voice sample datasets to improve R&D, and helps Sonde collect more data across platforms.
Digital Diagnostics, formerly IDx, is looking to expand into the skin health space with this new purchase.
The patient-facing EASE app is HIPAA compliant, and does not save any texts, photos or videos to the recipient's device.
After news broke about the $18.5 million deal all eyes in the digital health world have been on Livongo and Teladoc.
The company's smart insulin pen, dubbed the InPen, is slated to become part of Medtronics diabetes portfolio.
The MobiHealthNews team breaks down the week's big digital health news: Teladoc's proposed $18 billion acquisition of Livongo.
The deal is valued at roughly $4.7 billion.
Each Livongo share will be converted Teladoc stock at a 0.5920 exchange rate, plus an additional $11.44 in cash per stock.